K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · MRNA
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | MRNA | MODERNATX INC. | STANTON PARK GROUP | $50K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2026-04-20 | MRNA | MODERNA INC. | AVENUE SOLUTIONS | $50K | Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval; Issues related to FDA's delay in reviewing Moderna's flu vaccine |
| 2026-04-20 | MRNA | STANTON PARK GROUP LLC ON BEHALF OF MODERNATX INC. | DGSR LLC | $20K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2026-04-18 | MRNA | MODERNA US INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain |
| 2026-04-17 | MRNA | MODERNA INC. | MODERNA, INC. | $190K | Vaccine Policy, FDA Vaccine Approvals |
| 2026-04-15 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $80K | Issues related to vaccines, drug discovery, development and related issues. |
| 2026-04-10 | MRNA | MODERNA INC. | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2026-04-01 | MRNA | MODERNATX INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 41, 45C, 951A, 250, and 174. (H.R. 1414). |
| 2026-03-23 | MRNA | MODERNA INC. | MODERNA, INC. | $100K | Vaccine Policy |
| 2026-01-20 | MRNA | MODERNATX INC. | STANTON PARK GROUP | $50K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2026-01-20 | MRNA | MODERNA INC. | AVENUE SOLUTIONS | $50K | Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval |
| 2026-01-20 | MRNA | STANTON PARK GROUP LLC ON BEHALF OF MODERNATX INC. | DGSR LLC | $20K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2026-01-16 | MRNA | MODERNA INC. | MODERNA, INC. | $130K | Vaccine Policy Expansion of U.S. manufacturing |
| 2026-01-16 | MRNA | MODERNA US INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain |
| 2026-01-16 | MRNA | MODERNATX INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP) | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 45C, 951A, 250, and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1414, H.R. 1 - Sections 70231, 70322, 70323, 70302). |
| 2026-01-13 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $50K | Issues related to vaccines, drug discovery, development and related issues. |
| 2026-01-13 | MRNA | MODERNA INC. | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-10-20 | MRNA | MODERNATX INC. | STANTON PARK GROUP | $50K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-10-20 | MRNA | MODERNA INC. | AVENUE SOLUTIONS | $50K | Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to vaccine safety and approval |
| 2025-10-20 | MRNA | STANTON PARK GROUP LLC ON BEHALF OF MODERNATX INC. | DGSR LLC | $20K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-10-16 | MRNA | MODERNA INC. | MODERNA, INC. | $100K | Vaccine Policy |
| 2025-10-16 | MRNA | MODERNA US INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain |
| 2025-10-15 | MRNA | MODERNA INC. | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-10-14 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $80K | Issues related to vaccines, drug discovery, development and related issues. |
| 2025-10-13 | MRNA | MODERNATX INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP) | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 164(a), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1 - Sections 70231, 70322, 70323, 70302). |
| 2025-07-21 | MRNA | MODERNATX INC. | STANTON PARK GROUP | $50K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-07-21 | MRNA | MODERNA INC. | AVENUE SOLUTIONS | $50K | Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to bivalent vaccines; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues related to 2024 Physician Fee Schedule; H.R. 946/S. 1862, Orphan Cures Act |
| 2025-07-21 | MRNA | STANTON PARK GROUP LLC ON BEHALF OF MODERNATX INC. | DGSR LLC | $20K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-07-18 | MRNA | MODERNA US INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain |
| 2025-07-17 | MRNA | MODERNA INC. | MODERNA, INC. | $120K | Vaccine Policy Generally |
| 2025-07-15 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $100K | Issues related to vaccines, drug discovery, development and related issues. |
| 2025-07-13 | MRNA | MODERNA INC. | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-07-10 | MRNA | MODERNATX INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP) | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 164(a), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1 - Sections 70231, 70322, 70323, 70302). |
| 2025-04-30 | MRNA | MODERNA INC. | MODERNA, INC. | $70K | Foreign Direct Investment (Taiwan) Vaccines Policy; Long COVID Policy; Annual Flu and COVID Vaccines Approval |
| 2025-04-21 | MRNA | MODERNA US INC. FORMERLY REPORTED AS MODERNATX INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain Issues related to international vaccine deployment |
| 2025-04-21 | MRNA | MODERNATX INC. | STANTON PARK GROUP | $50K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-04-21 | MRNA | MODERNA INC. | AVENUE SOLUTIONS | $50K | Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to bivalent vaccines; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4); Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; |
| 2025-04-21 | MRNA | STANTON PARK GROUP LLC ON BEHALF OF MODERNATX INC. | DGSR LLC | $10K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-04-18 | MRNA | MODERNA INC. | MODERNA, INC. | $60K | Vaccine Policy Generally |
| 2025-04-17 | MRNA | MODERNATX INC. | THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP) | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 174 and 41. (H.R. 1990, H.R. 1062). |
| 2025-04-12 | MRNA | MODERNA INC. | HOLLAND & KNIGHT LLP | $20K | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-04-11 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $50K | Issues related to vaccines, drug discovery, development and related issues. |
| 2025-04-11 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $20K | Issues related to vaccines, drug discovery, development and related issues. |
| 2025-04-10 | MRNA | MODERNA US INC. | HEALTH POLICY SOURCE, INC. | $0 | Issues related to vaccines, drug discovery, development and related issues. |
| 2025-03-31 | MRNA | STANTON PARK GROUP LLC ON BEHALF OF MODERNATX INC. | DGSR LLC | $0 | Issues related to COVID-19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-03-06 | MRNA | MODERNA INC. | HOLLAND & KNIGHT LLP | $0 | Tax Reform - Restoring the Orphan Drug Tax Credit. |
| 2025-01-21 | MRNA | MODERNATX INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain Issues related to international vaccine deployment |
| 2025-01-21 | MRNA | MODERNATX INC. | STANTON PARK GROUP | $50K | Issues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues. |
| 2025-01-21 | MRNA | MODERNA INC. | AVENUE SOLUTIONS | $50K | Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to bivalent vaccines; Expiring health extenders; H.R. 10545, American Relief Act, 2025 |